How hidden silos across the sponsor-CRO partnership allow risks to remain invisible until they become timeline, quality or delivery issues
Why changing the outsourcing model rarely fixes the underlying problem when FSP, full service, milestone-based, outcome-based and hybrid partnerships can all encounter the same execution gaps
How to close the gap between knowing about a risk and actually acting on it, with clearer ownership of who decides, who acts and when
Practical ways sponsors can gain earlier visibility into capacity, quality signals, competing priorities and delivery risks without creating another layer of oversight
How to manage the partnership itself as an operational workstream, with shared ownership of risks, decisions and outcomes rather than relying on governance meetings to create alignment
Delay: Stalled trials can cost from $56,000 a day in early phase to millions a day late stage. Opening new sites adds months and cost.
24-hour activation: Go live in 24 hours on the sites you already have.
Patient matching: Algorithmic matching, geolocated to your active sites. Highly screened AI-match referrals only. Quality over volume, to protect site workload.
Specialist engagement: Referring specialists engaged, to streamline the site review process.
Security and transparency: Salesforce Health Cloud, built to support sites from referral to enrollment and randomization. Full progress visibility for sponsors, CROs and sites.
How well‑designed digital measures deliver measurable ROI in clinical trials by reducing missing data, improving statistical power, accelerating timelines, and preventing costly trial rework or failure.
How an end‑to‑end Wearable Sensor CRO delivery model integrates scientific strategy, operational oversight, and analytics to consistently produce regulatory‑ready datasets.
Real‑world case examples showing how proactive compliance monitoring and fit‑for‑purpose algorithms dramatically improve data completeness and statistical power.
The critical role of disease‑specific digital endpoint design versus off‑the‑shelf wearable algorithms in capturing meaningful treatment effects.
Practical guidance for clinical operations and outsourcing teams on reducing sponsor burden while scaling wearable technologies across global trials.
